| Phase 01 trial |
|
Phase 0
|
NCT05567679 |
Dec 2023 → Dec 2025 |
prostate cancer |
Edwin Posadas, MD |
Withdrawn
|
No outcome recorded
|
| Phase 118 trials |
|
Phase 1
|
NCT05983965 |
Sep 2024 → Mar 2026 |
T-cell non-Hodgkin lymphoma |
University of Alabama at Birmingham |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05934838 |
Oct 2023 → May 2026 overdue |
diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma |
Weill Medical College of Cornell University |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05627232 |
Aug 2023 → Jan 2028 expected |
acute myeloid leukemia |
Thomas Jefferson University |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05618366 |
Jun 2023 → Feb 2026 |
diffuse large B-cell lymphoma, follicular lymphoma |
Weill Medical College of Cornell University |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT05774886 |
May → Sep 2023 |
female breast carcinoma, triple-negative breast carcinoma |
Dana-Farber Cancer Institute |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT05627245 |
Mar 2023 → Sep 2026 expected |
diffuse large B-cell lymphoma germinal center B-cell type, follicular lymphoma, primary cutaneous T-cell lymphoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05353439 |
Jul 2022 → Feb 2026 overdue |
small cell lung carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04846478 |
Jun 2021 → Sep 2025 overdue |
castration-resistant prostate carcinoma, metastatic prostate carcinoma |
Dana-Farber Cancer Institute |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT04624113 |
Apr 2021 → Aug 2022 |
head and neck squamous cell carcinoma |
Washington University School of Medicine |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04537715 |
Apr 2020 → Apr 2023 |
diffuse large B-cell lymphoma, epithelioid sarcoma, follicular lymphoma, kidney medullary carcinoma +3 |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04241835 |
Jan 2020 → Mar 2025 |
cancer |
Epizyme, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04204941 |
Dec 2019 → Jun 2024 |
epithelioid sarcoma |
Epizyme, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03010982 |
Jun 2018 → Jan 2019 |
follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary mediastinal large B-cell lymphoma |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03217253 |
Mar 2018 → Sep 2019 |
B-cell non-Hodgkin lymphoma, hepatocellular carcinoma, metastatic malignant neoplasm |
National Cancer Institute (NCI) |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT03028103 |
Mar 2017 → Oct 2019 |
diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, mediastinal malignant lymphoma |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03009344 |
Jan → Jul 2017 |
B-cell non-Hodgkin lymphoma |
Eisai Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02601937 |
Jan 2016 → Jun 2021 |
extrarenal rhabdoid tumor, synovial sarcoma |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02220842 |
Dec 2014 → Jan 2020 |
lymphoma |
Hoffmann-La Roche |
Completed
|
No outcome recorded
|
|
| Phase 1/212 trials |
|
Phase 1/2
|
NCT07209163 |
Oct 2025 → Mar 2026 overdue |
peripheral T-cell lymphoma, not otherwise specified |
Ruijin Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05407441 |
Aug 2023 → Feb 2027 expected |
atypical teratoid rhabdoid tumor, chordoma, epithelioid sarcoma, rhabdoid tumor of the kidney |
Susan Chi, MD |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05152459 |
May 2023 → Dec 2024 |
follicular lymphoma |
City of Hope Medical Center |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT05551936 |
Jan 2023 → May 2026 overdue |
follicular lymphoma |
Vaishalee Kenkre |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05604417 |
Jan 2023 → Dec 2024 |
follicular lymphoma |
Jacob Soumerai, MD |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT05372354 |
Oct 2022 → Oct 2026 expected |
plasma cell myeloma |
Bristol-Myers Squibb |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04557956 |
Aug 2021 → Oct 2025 overdue |
cutaneous melanoma, metastatic melanoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03854474 |
Nov 2019 → Jun 2027 expected |
urinary bladder carcinoma, urothelial carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04179864 |
Nov 2019 → Nov 2024 |
castration-resistant prostate carcinoma, metastatic prostate carcinoma |
Epizyme, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT02889523 |
Oct 2016 → Jan 2023 overdue |
diffuse large B-cell lymphoma, follicular lymphoma |
The Lymphoma Academic Research Organisation |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT02875548 |
Aug 2016 → Sep 2025 |
diffuse large B-cell lymphoma, epithelioid sarcoma, follicular lymphoma, kidney medullary carcinoma +2 |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01897571 |
Jun 2013 → Aug 2021 |
follicular lymphoma, primary mediastinal large B-cell lymphoma |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
| Phase 220 trials |
|
Phase 2
|
NCT06068881 |
Sep 2025 → Apr 2029 |
follicular lymphoma |
Epizyme, Inc. |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT06575686 |
Mar 2025 → Jul 2028 |
B-cell non-Hodgkin lymphoma |
City of Hope Medical Center |
Suspended
|
No outcome recorded
|
|
Phase 2
|
NCT06692452 |
Dec 2024 → Oct 2027 |
angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified |
Eric Jacobsen, MD |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT06242834 |
Sep 2024 → Apr 2027 expected |
aggressive B-cell non-Hodgkin lymphoma |
Northwestern University |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05994235 |
Nov 2023 → Oct 2033 expected |
follicular lymphoma |
Weill Medical College of Cornell University |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05890352 |
Sep 2023 → Dec 2026 expected |
high grade B-cell lymphoma, high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement |
SWOG Cancer Research Network |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05151588 |
Sep 2023 → Aug 2026 overdue |
nasal cavity and paranasal sinus carcinoma |
Dr. Victor H.F. Lee |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05713110 |
Feb 2023 → Dec 2024 |
lymphoma |
Hutchmed |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05467943 |
Jul 2022 → Nov 2024 |
B-cell non-Hodgkin lymphoma |
Hutchmed |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT05023655 |
Jan 2022 → Mar 2026 |
cancer |
Prisma Health-Upstate |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT05018975 |
Jan 2022 → Sep 2023 |
acute respiratory distress syndrome, cytokine release syndrome |
Loma Linda University |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT04917042 |
Aug 2021 → Feb 2025 overdue |
nerve sheath neoplasm |
University of Florida |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT04705818 |
Jul 2021 → Jan 2024 |
colorectal cancer, pancreatic adenocarcinoma, soft tissue sarcoma |
Institut Bergonié |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT04762160 |
Dec 2020 → Mar 2022 |
follicular lymphoma |
Epizyme, Inc. |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03348631 |
May 2019 → Jul 2023 overdue |
endometrial endometrioid adenocarcinoma, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, uterine corpus cancer |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03456726 |
Apr 2018 → Dec 2021 |
B-cell non-Hodgkin lymphoma |
Eisai Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03213665 |
Nov 2017 → Mar 2022 |
Ewing sarcoma, Hodgkins lymphoma, Langerhans cell histiocytosis, Wilms tumor +11 |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03155620 |
Jul 2017 → Mar 2025 overdue |
Ewing sarcoma, Langerhans cell histiocytosis, Wilms tumor, conventional osteosarcoma +13 |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT02860286 |
Jul 2016 → Jun 2018 |
BAP1-related tumor predisposition syndrome, mesothelioma |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02601950 |
Dec 2015 → Feb 2024 |
atypical teratoid rhabdoid tumor, epithelioid sarcoma, kidney medullary carcinoma, poorly differentiated chordoma +2 |
Epizyme, Inc. |
Completed
|
No outcome recorded
|
|
| Phase 31 trial |
|
Phase 3
|
NCT04224493 |
Jun 2020 → Feb 2027 expected |
follicular lymphoma |
Epizyme, Inc. |
Active not recruiting
|
No outcome recorded
|
| Phase not stated1 trial |
| — |
NCT03874455 |
— |
atypical teratoid rhabdoid tumor, chondrosarcoma, desmoplastic small round cell tumor, epithelioid malignant peripheral nerve sheath tumor +12 |
Epizyme, Inc. |
No longer available
|
No outcome recorded
|